Literature DB >> 26749283

TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.

Xiu-Guo Han1, Yan Li1, Hui-Min Mo2, Kang Li1, Du Lin3, Chang-Qing Zhao1, Jie Zhao4, Ting-Ting Tang5.   

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) inhibit matrix metalloproteinases (MMPs) to limit degradation of the extracellular matrix. Low levels of TIMP3 have been demonstrated in cancer tissues at advanced clinical stages, with positive distant metastasis and chemotherapeutic resistance. We examined the role of TIMP3 in osteosarcoma (OS) cell invasiveness and chemoresistance. TIMP3 was overexpressed or knocked down in the human OS cell lines Saos2 and MG63. Cell migration and invasion capacities were then evaluated using Transwell assays, and resistance to cisplatin was assessed by CCK-8 assay and flow cytometry. Real-time PCR and western blotting were used to investigate activation of signaling pathways downstream of TIMP3. Overexpression of TIMP3 inhibited the migration and invasion of Saos2 and MG63 cells, while knockdown of TIMP3 had the opposite effect. Cell survival after exposure to cisplatin was inhibited by TIMP3 overexpression in both Saos2 and MG63 cells. Consistently, downregulation of TIMP3 gene expression significantly decreased the sensitivity of OS cells to cisplatin treatment. MMP1, MMP2, Bcl-2, and Akt1 were all downregulated following TIMP3 overexpression, while Bax and cleaved caspase-3 were upregulated. TIMP3 knockdown had opposite effects on the regulation of these genes. Taken together, our findings suggest TIMP3 as a new target for inhibition of OS progression and chemotherapeutic resistance.

Entities:  

Keywords:  Cisplatin sensitivity; Invasion; Migration; Osteosarcoma; TIMP3

Mesh:

Substances:

Year:  2016        PMID: 26749283     DOI: 10.1007/s13277-015-4757-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

Review 1.  Cell Death Signaling.

Authors:  Douglas R Green; Fabien Llambi
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-12-01       Impact factor: 10.005

2.  Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosarcoma cells.

Authors:  Ryuichiro Kimura; Chie Ishikawa; Takayoshi Rokkaku; Ralf Janknecht; Naoki Mori
Journal:  Biochim Biophys Acta       Date:  2011-05-27

3.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

Authors:  R Gan; Y Yang; X Yang; L Zhao; J Lu; Q H Meng
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

4.  Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.

Authors:  Jian Hua Qi; Bela Anand-Apte
Journal:  Apoptosis       Date:  2015-04       Impact factor: 4.677

5.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 6.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

7.  Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Authors:  Angela Zöllinger; Thorsten Stühmer; Manik Chatterjee; Stefan Gattenlöhner; Eugenia Haralambieva; Hans-Konrad Müller-Hermelink; Mindaugas Andrulis; Axel Greiner; Carmen Wesemeier; Jörg C Rath; Hermann Einsele; Ralf C Bargou
Journal:  Blood       Date:  2008-07-17       Impact factor: 22.113

Review 8.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

9.  Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth.

Authors:  Yoshinobu Saitoh; Takao Setoguchi; Masahito Nagata; Arisa Tsuru; Shunsuke Nakamura; Satoshi Nagano; Yasuhiro Ishidou; Hiroko Nagao-Kitamoto; Masahiro Yokouchi; Shingo Maeda; Akihide Tanimoto; Tatsuhiko Furukawa; Setsuro Komiya
Journal:  Int J Oncol       Date:  2015-11-06       Impact factor: 5.650

10.  Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.

Authors:  Qing-Lian Tang; Xian-Biao Xie; Jin Wang; Qiong Chen; An-Jia Han; Chang-Ye Zou; Jun-Qiang Yin; Da-Wei Liu; Yi Liang; Zhi-Qiang Zhao; Bi-Cheng Yong; Ru-Hua Zhang; Qi-Sheng Feng; Wu-Guo Deng; Xiao-Feng Zhu; Binhua P Zhou; Yi-Xin Zeng; Jing-Nan Shen; Tiebang Kang
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

View more
  13 in total

1.  Identification of candidate biomarkers for epithelial ovarian cancer metastasis using microarray data.

Authors:  Su Li; Hua Li; Ying Xu; Xiaomei Lv
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

2.  MicroRNA-221 promotes proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) by targeting tissue inhibitor of metalloproteinases-3 (TIMP3).

Authors:  Yan Yan; Ying Xu; Gehui Ni; Siqi Wang; Xinli Li; Juan Gao; Haifeng Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

3.  Carthamin yellow inhibits matrix degradation and inflammation induced by LPS in the intervertebral disc via suppression of MAPK pathway activation.

Authors:  Bin Chen; Han-Tao Wang; Bo Yu; Ji-Dong Zhang; Yu Feng
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

4.  TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production.

Authors:  Xiu-Guo Han; Hui-Min Mo; Xu-Qiang Liu; Yan Li; Lin Du; Han Qiao; Qi-Ming Fan; Jie Zhao; Shu-Hong Zhang; Ting-Ting Tang
Journal:  Front Genet       Date:  2018-04-20       Impact factor: 4.599

5.  miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3.

Authors:  Jianping Guo; Quanxiang Liu; Zengxin Li; Haifeng Guo; Changshuang Bai; Fajia Wang
Journal:  Onco Targets Ther       Date:  2018-12-03       Impact factor: 4.147

6.  Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.

Authors:  Zhen Li; Jian-Ni Yao; Wen-Ting Huang; Rong-Quan He; Jie Ma; Gang Chen; Qing-Jun Wei
Journal:  Mol Med Rep       Date:  2018-12-13       Impact factor: 2.952

7.  Ginsenoside Rh1 inhibits colorectal cancer cell migration and invasion in vitro and tumor growth in vivo.

Authors:  Xi Lyu; Xiaodong Xu; Ailin Song; Jinyi Guo; Yawu Zhang; Youcheng Zhang
Journal:  Oncol Lett       Date:  2019-08-14       Impact factor: 2.967

8.  Assessment of prognostic value of tissue inhibitors of metalloproteinase 3 (TIMP3) protein in ovarian cancer.

Authors:  Sahar Hakamy; Mourad Assidi; Mohammad A Jafri; Taoufik Nedjadi; Heba Alkhatabi; Abrar Al-Qahtani; Jaudah Al-Maghrabi; Khalid Sait; Mohammed Al-Qahtani; Abdelbaset Buhmeida; Adeel Chaudhary
Journal:  Libyan J Med       Date:  2021-12       Impact factor: 1.657

9.  Loss of TIMP3 by promoter methylation of Sp1 binding site promotes oral cancer metastasis.

Authors:  Chun-Wen Su; Yu-Chao Chang; Ming-Hsien Chien; Yi-Hsien Hsieh; Mu-Kuan Chen; Chiao-Wen Lin; Shun-Fa Yang
Journal:  Cell Death Dis       Date:  2019-10-17       Impact factor: 8.469

Review 10.  Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Authors:  Timothy M Fan; Ryan D Roberts; Michael M Lizardo
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.